Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

TB targeted in ICB&DD, Sanofi collaboration
March 2012
SHARING OPTIONS:

STONY BROOK, N.Y.—Iowa Jimi, director of the Institute of Chemical Biology & Drug Discovery (ICB&DD) and a distinguished professor of chemistry at Stony Brook University, has announced the establishment of a multi-year research collaboration with Sanofi for a potential treatment for tuberculosis and other bacterial infections. Ojima and a team of ICB&DD researchers have identified novel compounds that can inhibit bacterial cell division by interfering with FtsZ, a cellular protein responsible for bacterial cell maintenance and division. Interference of FtsZ renders bacteria incapable of maintenance, division and propagation, and along with Sanofi, ICB&DD researchers are working to optimize the compounds to identify drug candidates for clinical development in treating tuberculosis, particularly multidrug-resistant strains.  
 
"This is an exciting collaboration as we partner with a global pharmaceutical leader in developing a new and efficacious TB drug," said Ojima.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.